TABLE 2.
Baseline Demographic and Clinical Characteristics of Included Patients according to Disease‐Modifying Therapy Received
| Characteristic | No Therapy, n = 151 | IFN, n = 73 | GA, n = 70 | Teri, n = 64 | DMF, n = 174 | FTY, n = 94 | Nat, n = 85 | Anti‐CD20, n = 94 a | Other, n = 39 |
|---|---|---|---|---|---|---|---|---|---|
| Age, mean (SD) | 53.4 (13.4) | 47.5 (10.5) | 45.7 (11.3) | 49.1 (9.4) | 41.4 (10.9) | 44.2 (9.5) | 37.9 (9.8) | 42.0 (10.0) | 42.2 (13.8) |
| Female sex, n (%) | 104 (68.9) | 53 (72.6) | 48 (68.6) | 44 (68.8) | 114 (65.5) | 74 (78.7) | 64 (75.3) | 64 (68.1) | 28 (71.8) |
| BMI, mean (SD) | 24.6 (4.6) | 24.3 (2.7) | 25.2 (5.0) | 24.7 (4.5) | 23.3 (4.1) | 23.9 (5.2) | 22.7 (4.1) | 22.6 (3.7) | 23.2 (3.8) |
| MS phenotype, n (%) | |||||||||
| Primary progressive | 22 (14.6) | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 2 (2.1) | 1 (1.2) | 16 (17.0) | 2 (5.1) |
| Relapsing–remitting | 65 (43.0) | 65 (89.0) | 64 (91.4) | 59 (92.2) | 165 (94.8) | 81 (86.2) | 83 (97.6) | 67 (71.3) | 27 (69.2) |
| Secondary progressive | 47 (31.1) | 6 (8.2) | 2 (2.9) | 3 (4.7) | 5 (2.9) | 9 (9.6) | 0 (0.0) | 9 (9.6) | 10 (25.6) |
| Missing data | 17 (11.3) | 2 (2.7) | 3 (4.3) | 2 (3.1) | 4 (2.3) | 2 (2.1) | 1 (1.2) | 2 (2.1) | 0 (0.0) |
| MS disease duration, median yr (IQR) | 16.2 (8–23) | 12.0 (6–19) | 10.1 (5–17) | 11.4 (6–15) | 5.5 (3–13) | 11.8 (7–18) | 9.1 (5–15) | 8.2 (4–13) | 12.9 (5–18) |
| EDSS, median (IQR) | 5.5 (2–7) | 1.5 (1–2.5) | 1.5 (1–2) | 2.0 (1.5–3) | 1.5 (1–2) | 2.0 (1.5–3) | 2.0 (1.5–3) | 3.0 (1.5–4.5) | 3.0 (1.5–6) |
| Methylprednisolone, b n (%) | 9 (6.0) | 2 (2.7) | 1 (1.4) | 2 (3.1) | 4 (2.3) | 4 (4.3) | 1 (1.2) | 1 (1.1) | 2 (5.1) |
a
Ocrelizumab or rituximab.
b
One month before symptoms onset.
BMI = body mass index; DMF = dimethyl fumarate; EDSS = Expanded Disability Status Scale; FTY = fingolimod; GA = glatiramer‐acetate; IFN = interferon; IQR = interquartile range; MS = multiple sclerosis; Nat = natalizumab; SD = standard deviation; Teri = teriflunomide.